A Phase 3b Open-Label Study Designed to Evaluate Tear Production Stimulated by 0.003% AR-15512
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs Acoltremon (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Alcon Research
- 03 Feb 2025 Status changed from recruiting to completed.
- 07 Jan 2025 Planned End Date changed from 1 Mar 2025 to 1 Jan 2025.
- 07 Jan 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jan 2025.